QIAGEN Backs UK Initiative to Sequence 100,000 Newborn Genomes QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has announced a strategic partnership with Genomics England to support the ambitious Generation Study, a groundbreaking initiative aiming to sequence the genomes of 100,000…
Partnering for Bispecific Antibodies and ADCs: Biocytogen and Acepodia Biocytogen (HKEX: 02315) and Acepodia (6976:TT) have announced a strategic partnership aimed at jointly evaluating a dual-payload bispecific antibody-drug conjugate (BsAD2C) program. This collaboration marks a significant step forward in their…
Wearable Data Integrated into EHR for Personalized Care by Validic At CES, Validic, a leader in digital health and personalized care technology, unveiled a new integration of physical activity data from wearables and smartwatches into electronic health record (EHR) systems.…
Viz.ai Partners with 3 Pharma Companies, Expands to 60,000 Providers Viz.ai, a leader in AI-powered disease detection and care coordination, has announced major achievements in its mission to revolutionize healthcare delivery. In 2024, the company formed partnerships with three of…
Patient Engagement Enhanced as Swoop Acquires MyHealthTeam Swoop, a leader in AI-driven healthcare marketing, has announced its acquisition of MyHealthTeam, the creator of one of the largest, most engaged opted-in patient social networks in the U.S. This acquisition is a…
Detection of Hyperkalemia Powered by AI Receives FDA Breakthrough Designation AccurKardia, a leading innovator in ECG-based diagnostic technology, has announced that its AI-powered AK+ Guard™ hyperkalemia detection software has received Breakthrough Device Designation from the U.S. Food and Drug Administration…
Diality Treats First Patient with Moda-flx Hemodialysis System Diality, a cutting-edge medical device company specializing in smart, flexible hemodialysis platforms, has announced the successful completion of the first-ever patient treatment with its Moda-flx Hemodialysis System™. This milestone was achieved in…
Stoke Therapeutics Announces Phase 3 Study Plans for Zorevunersen in Dravet Syndrome Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on RNA medicine to restore protein expression, announced today that it has finalized its Phase 3 EMPEROR study design…
Heart Failure Program and Leadership Change Announced by RyCarma RyCarma Therapeutics, Inc., formerly known as ARMGO Pharma, is a clinical-stage biotech company focused on developing first-in-class small molecule therapeutics for cardiovascular and skeletal muscle diseases. Today, the company announced its…
Announces REZZAYO® Approval in Spain for Invasive Candidiasis Treatment by Mundipharma Mundipharma announces today that Spain’s Ministry of Health has approved reimbursement for REZZAYO® (rezafungin acetate) as a treatment for invasive candidiasis in adults. This announcement follows the European Commission’s…
Arcturus Begins Phase 2 Dosing for CF and OTC Deficiency Arcturus Therapeutics Holdings Inc., a pioneering company in mRNA medicine, announced that it has initiated Phase 2 multiple ascending dose studies for two major conditions—cystic fibrosis (CF) and ornithine transcarbamylase…
Collaboration Between Team Gleason and Synchron Expands BCI Efforts Synchron, a leading brain-computer interface (BCI) company, and Team Gleason, a foundation focused on enhancing the lives of individuals living with Amyotrophic Lateral Sclerosis (ALS), have expanded their partnership to promote…